Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24


Correlation of Transabdominal Ultrasonography and Cystoscopy in Follow-up of Patients with Non-muscle Invasive Bladder Cancer.

Puneet A, Balagopal N, Ginil K, Georgie M, Sanjeevan KV, Appu T.

Indian J Surg Oncol. 2017 Dec;8(4):548-553. doi: 10.1007/s13193-017-0678-6. Epub 2017 Jul 21.


Anaesthesia of the posterior urethra and pain reduction during cystoscopy - a randomized controlled trial.

Poletajew S, Bender S, Pudełko P, Łykowski M, Piecha T, Sutkowski B, Radziszewski P.

Wideochir Inne Tech Maloinwazyjne. 2017;12(1):75-80. doi: 10.5114/wiitm.2017.66506. Epub 2017 Mar 13.


How different cystoscopy methods influence patient sexual satisfaction, anxiety, and depression levels: a randomized prospective trial.

Krajewski W, Kościelska-Kasprzak K, Rymaszewska J, Zdrojowy R.

Qual Life Res. 2017 Mar;26(3):625-634. doi: 10.1007/s11136-016-1493-1. Epub 2017 Jan 3.


The Role of Population-Based Observational Research in Bladder Cancer.

Robinson AG, Izard JP, Booth CM.

Bladder Cancer. 2015 Oct 26;1(2):123-131. Review.


A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance.

Sapre N, Macintyre G, Clarkson M, Naeem H, Cmero M, Kowalczyk A, Anderson PD, Costello AJ, Corcoran NM, Hovens CM.

Br J Cancer. 2016 Feb 16;114(4):454-62. doi: 10.1038/bjc.2015.472. Epub 2016 Jan 26.


Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer.

Smith SG, Koppolu BP, Ravindranathan S, Kurtz SL, Yang L, Katz MD, Zaharoff DA.

Cancer Immunol Immunother. 2015 Jun;64(6):689-96. doi: 10.1007/s00262-015-1672-x. Epub 2015 Mar 10.


Stepwise application of urine markers to detect tumor recurrence in patients undergoing surveillance for non-muscle-invasive bladder cancer.

Todenhöfer T, Hennenlotter J, Esser M, Mohrhardt S, Aufderklamm S, Böttge J, Rausch S, Mischinger J, Bier S, Gakis G, Kuehs U, Stenzl A, Schwentner C.

Dis Markers. 2014;2014:973406. doi: 10.1155/2014/973406. Epub 2014 Dec 22.


Identification of γ-synuclein as a stage-specific marker in bladder cancer by immunohistochemistry.

Zhao J, Xing N.

Med Sci Monit. 2014 Dec 5;20:2550-5. doi: 10.12659/MSM.892927.


Patterns of surveillance imaging after nephrectomy in the Medicare population.

Feuerstein MA, Atoria CL, Pinheiro LC, Huang WC, Russo P, Elkin EB.

BJU Int. 2016 Feb;117(2):280-6. doi: 10.1111/bju.12980. Epub 2015 Jun 22.


External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.

Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1804-12. doi: 10.1158/1055-9965.EPI-14-0029. Epub 2014 Jun 11.


Logic regression for provider effects on kidney cancer treatment delivery.

Banerjee M, Filson C, Xia R, Miller DC.

Comput Math Methods Med. 2014;2014:316935. doi: 10.1155/2014/316935. Epub 2014 Mar 27.


Educational opportunities in bladder cancer: increasing cystoscopic adherence and the availability of smoking-cessation programs.

Kowalkowski MA, Goltz HH, Petersen NJ, Amiel GE, Lerner SP, Latini DM.

J Cancer Educ. 2014 Dec;29(4):739-45. doi: 10.1007/s13187-014-0649-3.


Urinary protein biomarker panel for the detection of recurrent bladder cancer.

Rosser CJ, Chang M, Dai Y, Ross S, Mengual L, Alcaraz A, Goodison S.

Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1340-5. doi: 10.1158/1055-9965.EPI-14-0035. Epub 2014 Apr 8.


Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma.

Cussenot O, Sighar K, Mohammed M, Hugonin S, Ondet V, Larre S, Lacave R, Roupret M, Cancel-Tassin G.

World J Urol. 2014 Apr;32(2):551-7. doi: 10.1007/s00345-013-1191-3. Epub 2013 Nov 7.


Quality of care in patients with bladder cancer: a case report?

Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR, Litwin MS; Urologic Diseases in America Project.

Cancer. 2012 Mar 1;118(5):1412-21. doi: 10.1002/cncr.26402. Epub 2011 Aug 5.


Ethnic differences in bladder cancer survival.

Yee DS, Ishill NM, Lowrance WT, Herr HW, Elkin EB.

Urology. 2011 Sep;78(3):544-9. doi: 10.1016/j.urology.2011.02.042. Epub 2011 Jul 22.


Compliance with guidelines for patients with bladder cancer: variation in the delivery of care.

Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR, Litwin MS; Urologic Diseases in America Project.

Cancer. 2011 Dec 1;117(23):5392-401. doi: 10.1002/cncr.26198. Epub 2011 Jul 11.


Urine-based assays for the detection of bladder cancer.

Villicana P, Whiting B, Goodison S, Rosser CJ.

Biomark Med. 2009 Jun 1;3(3):265.


Racial differences in treatment and outcomes among patients with early stage bladder cancer.

Hollenbeck BK, Dunn RL, Ye Z, Hollingsworth JM, Lee CT, Birkmeyer JD.

Cancer. 2010 Jan 1;116(1):50-6. doi: 10.1002/cncr.24701.


Does treatment intensity matter in superficial bladder cancer? Consensus, clinical practice, and confounding.

Lyman GH, Kuderer NM, Freedland SJ.

J Natl Cancer Inst. 2009 Apr 15;101(8):543-5. doi: 10.1093/jnci/djp060. Epub 2009 Apr 7. No abstract available.

Supplemental Content

Support Center